CPX-351 has orphan drug status for the treatment of AML, according to the Celator Web site.
Celator Pharmaceuticals sponsored the trial. Dr. Lancet disclosed that his center received compensation from the company, and he has served on the board of directors or advisory committees. Two coauthors also disclosed serving on the board or as advisors, and one is employed by the company.